Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DORFEN
- Development stage
- Unknown
- Lead developer
- Aeromatic Healthcare
- Modality
- Small Molecules
- Administration
- Parenteral
01
Overview
**DORFEN** is an injectable fixed-dose bronchodilator combination developed by Aeromatic Healthcare containing **etofylline** and **theophylline**. Both active substances are methylxanthine derivatives; theophylline contributes bronchodilator activity principally through nonselective adenosine-receptor antagonism and phosphodiesterase inhibition, which can relax airway smooth muscle. The product is indicated for bronchospasm and asthma-related respiratory conditions.
- Brand names
- DORFEN
- Other names
- etofylline + theophylline
02
Targets
COXmAChR (Muscarinic acetylcholine receptors)
Beyond the preview
Go deeper on DORFEN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DORFEN.